{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper bound of the CI was not estimable for group due to low number of PFS events observed by the analysis time.","groupId":"OG000","lowerLimit":"14.7","upperLimit":"NA","value":"NA"},{"comment":"Median and upper bound of the CI was not estimable for group due to low number of PFS events observed by the analysis time.","groupId":"OG001","lowerLimit":"13.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"description":"PFS was defined as the time from first dose of IP until the earliest date of disease progression (PD) or death due to any cause. PD was per IMWG-URC, with progression assessments at intervals as per local standard of care.\n\nPD: increase of 25% from lowest response value in serum M-component and/or urine M-component and/or only in participants without measurable serum and urine M protein levels: the difference between involved and uninvolved free light chain (FLC) levels and/or only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow (BM) plasma cell percentage; definite development of new bone lesions or soft tissue plasmacytomas; development of hypercalcemia.\n\nMedians were estimated using the Kaplan-Meier method. Corresponding 95% confidence intervals (CIs) were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory multiple myeloma received a triplet combination of KRd.\n\nCarfilzomib was administered as a 10-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day treatment cycles. The starting dose of carfilzomib was 20 mg/m\\^2 on Days 1 and 2, and if tolerated, escalated to a target dose of 27 mg/m\\^2 starting on Day 8 of cycle 1 and thereafter. From cycle 13, the Day 8 and Day 9 doses of carfilzomib were omitted. After cycle 18, carfilzomib was discontinued.\n\nLenalidomide 25 mg was taken orally on Days 1 to 21 and dexamethasone 40 mg by mouth or IV infusion on Days 1, 8, 15, and 22 of repeated 28-day treatment cycles.","id":"OG000","title":"Carfilzomib, Lenalidomide and Dexamethasone (KRd)"},{"description":"Participants with relapsed or refractory multiple myeloma received a doublet combination of Kd.\n\nCarfilzomib was administered as a 30-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day treatment cycles. The starting dose of carfilzomib was 20 mg/m\\^2 on Days 1 and 2, and if tolerated, was escalated to a target dose of 56 mg/m\\^2 starting on Day 8 of cycle 1 and thereafter.\n\nDexamethasone 20 mg was taken by mouth or IV infusion on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle.","id":"OG001","title":"Carfilzomib and Dexamethasone (Kd)"}],"paramType":"MEDIAN","populationDescription":"Safety analysis set included all enrolled participants who received at least one dose of IP.","reportingStatus":"POSTED","timeFrame":"From enrollment until the end of trial or death date, whichever occurred earlier; median (min, max) time on trial was 8.7 (0.1, 37.2) months","title":"Progression Free Survival (PFS) as Per International Myeloma Working Group-Uniform Response Criteria (IMWG-URC)","type":"SECONDARY","unitOfMeasure":"months"}